In response to the AsthmaNet RFA, we have established the Atlantic Coast Consortium for Asthma (ACC-A) to serve as a clinical site. It consists of Wake Forest University Health Sciences (SP Peters, PI, Lead Investigator, Adults), University of Virginia (WG Teague, Co-PI, Lead Investigator, Children), Emory University (A Fitzpatrick, Co-I, Site Director), and North Carolina Clinical Research (C LaForce, Co-I, Medical Director). The group of investigators assembled has extensive experience as participants and lead investigators in national asthma networks including the Asthma Clinical Research Network (ACRN) 1 and 2, the Severe Asthma Research Program (SARP), the American Lung Association's Asthma Clinical Research Centers (ALA-ACRC), The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) program, and SNP Typing for Association with Multiple Phenotypes from Existing Epidemiologic Data (STAMPEED, Genome wide Association for Asthma and Lung Function), and with a wide variety of asthma clinical trials. With this experience and extensive resources, we agree to participate in all aspects of AsthmaNet and propose two major protocols (with companion exploratory and mechanistic protocols) focusing on specific sub-sets of severe asthmatics in adults and children. Gene-Based Anti-TNF Therapy in Severe Asthma (Gene BATTS) is a randomized, double-blind, placebo-controlled genotype-stratified trial in adults designed to test the hypothesis that severe asthmatics with specific genetic variants in tumor necrosis factor (TNF) receptor genes respond better to anti-TNF than patients without these variants. Management Options for Severe Asthma in Children (MOSAIC) is a randomized, double-blinded, parallel group trial designed to determine the efficacy of 3 treatment regimes: 880 meg/day fluticasone alone, 440 meg/day fluticasone + BID salmeterol, and 440 meg/day fluticasone + BID ipratropium bromide in severe asthmatic children inadequately controlled on fluticasone 440 meg/day. Companion protocols will examine corticosteroid resistance (RASS) and a possible genetic mechanism for resistance (IMMOST) in adults, and the efficacy of inhaled S-nitrosoglutathione (N30-201) (SNORT) in children.

Public Health Relevance

The Atlantic Coast Consortium for Asthma (ACC-A) and AsthmaNet have been established to perform clinical trials in adults and children with asthma, in order to define better treatment options for them. Through genetic, phenotypic (i.e. clinical), and other means, we hope to be able to identify the right asthma treatment forthe right patient, which both maximizes clinical benefit, and minimizes potential harm.

National Institute of Health (NIH)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Freemer, Michelle M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wake Forest University Health Sciences
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Ortega, Victor E; Meyers, Deborah A (2014) Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol 133:16-26
Sutherland, E Rand; Busse, William W; National Heart, Lung, and Blood Institute's AsthmaNet (2014) Designing clinical trials to address the needs of childhood and adult asthma: the National Heart, Lung, and Blood Institute's AsthmaNet. J Allergy Clin Immunol 133:34-8.e1
Castro, Mario; King, Tonya S; Kunselman, Susan J et al. (2014) Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA 311:2083-91
Ortega, V E (2014) Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management. Clin Genet 86:12-20
Szefler, Stanley J; Chmiel, James F; Fitzpatrick, Anne M et al. (2014) Asthma across the ages: knowledge gaps in childhood asthma. J Allergy Clin Immunol 133:3-13; quiz 14
Ortega, Victor E; Hawkins, Gregory A; Moore, Wendy C et al. (2014) Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting ? agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med 2:204-13
Ortega, Victor E; Meyers, Deborah A (2014) Implications of population structure and ancestry on asthma genetic studies. Curr Opin Allergy Clin Immunol 14:381-9
Phipatanakul, Wanda; Teague, W Gerald (2013) Xenon ventilation computed tomography rules: new technology may open up further understanding in asthma. Ann Allergy Asthma Immunol 111:81
Pascual, Rodolfo M; Peters, Stephen P (2011) Asthma. Med Clin North Am 95:1115-24
Bleecker, Eugene R; Siler, Thomas; Owen, Roger et al. (2011) Bronchodilator efficacy and safety of indacaterol 150 ?g once daily in patients with COPD: an analysis of pooled data. Int J Chron Obstruct Pulmon Dis 6:431-8

Showing the most recent 10 out of 11 publications